Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
Jessica M Bright, Holly J Carlisle, Alyssa M A Toda, Molly Murphy, Tyler P Molitor, Paul Wren, Kristin M Andruska, Enchi Liu, Carrolee Barlow, Jessica M Bright, Holly J Carlisle, Alyssa M A Toda, Molly Murphy, Tyler P Molitor, Paul Wren, Kristin M Andruska, Enchi Liu, Carrolee Barlow
Abstract
Background: A common genetic mutation that causes Parkinson's disease (PD) is the G2019S LRRK2 mutation. A precision medicine approach that selectively blocks only excess kinase activity of the mutant allele could yield a safe and effective treatment for G2019S LRRK2 PD.
Objective: To determine the activity of a G2019S mutant selective leucine-rich repeat kinase 2 (LRRK2) kinase inhibitor as compared to a nonselective inhibitor in blood of subjects with genetic and idiopathic PD on two LRRK2 biomarkers, pSer935 LRRK2 and pThr73 Rab10.
Methods: Blood was collected from 13 subjects with or without a G2019S LRRK2 mutation with PD and one healthy control. Peripheral blood mononuclear cells were treated ex vivo with a novel G2019S LRRK2 inhibitor (EB-42168) or the nonselective inhibitor MLi-2. Quantitative western immunoblot analyses were performed.
Results: EB-42168 was 100 times more selective for G2019S LRRK2 when compared to wild-type (WT) LRRK2. Concentrations that inhibited phosphorylation of pSer935 LRRK2 by 90% in homozygous G2019S LRRK2 patients, inhibited pSer935 LRRK2 by 36% in heterozygous patients, and by only 5% in patients carrying only the WT allele. Similar selectivity was seen for pThr73 Rab10. MLi-2 showed an equivalent level of inhibition across all genotypes.
Conclusions: These findings demonstrate that EB-42168, a G2019S LRRK2 selective inhibitor, lowers mutant G2019S LRRK2 phosphorylated biomarkers while simultaneously sparing WT LRRK2. Selective targeting of G2019S LRRK2 with a small molecule lays the foundation for a precision medicine treatment of G2019S LRRK2 PD. © 2021 ESCAPE Bio, Inc. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keywords: G2019S LRRK2; Parkinson's disease; biomarker; peripheral blood mononuclear cells; pharmacodynamic.
© 2021 ESCAPE Bio, Inc. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Figures
References
- Paisán‐Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8‐linked Parkinson's disease. Neuron 2004;44:595–600.
- Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal‐dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601–607.
- Domingo A, Klein C. Chapter 14 genetics of Parkinson disease. Handb Clin Neurology 2018;147:211–227.
- Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329–341.
- Sheng Z, Zhang S, Bustos D, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 2012;4:164ra161.
- Kluss JH, Conti MM, Kaganovich A, et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. Npj Park Dis 2018;4:13.
- Fan Y, Howden AJM, Sarhan AR, et al. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J 2018;475:23–44.
- Steger M, Tonelli F, Ito G, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 2016;5:e12813.
- Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 2020;16:97–107.
- West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol 2017;298:236–245.
- Karayel Ö, Tonelli F, Virreira Winter S. Accurate MS‐based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease. Molecular & Cellular Proteomics. 2020;19:1546–1560. 10.1074/mcp.ra120.002055
- Padmanabhan S, Lanz TA, Gorman D, et al. An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson's disease and G2019S LRRK2 cohorts. J Park Dis 2020;10:623–629.
- Rideout HJ, Chartier‐Harlin M‐C, Fell MJ, et al. The current state‐of‐the art of LRRK2‐based biomarker assay development in Parkinson's disease. Front Neurosci‐Switz 2020;14:865.
- Fell MJ, Mirescu C, Basu K, et al. MLi‐2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 2015;355:397–409.
- Garofalo AW, Bright J, De Lombaert S, et al. Selective Inhibitors of G2019S‐LRRK2 Kinase Activity. J Med Chem 2020;63:14821–14839. 10.1021/acs.jmedchem.0c01243
- Fuji RN, Flagella M, Baca M, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 2015;7:273ra15.
- Baptista MAS, Merchant K, Barrett T, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med 2020;12:eaav0820.
- Whiffin N, Armean IM, Kleinman A, et al. The effect of LRRK2 loss‐of‐function variants in humans. Nat Med 2020;26:869–877.
- Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2‐associated Parkinson's disease: a case‐control study. Lancet Neurol 2008;7:583–590.
- Perera G, Ranola M, Rowe DB, Halliday GM, Dzamko N. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Sci Rep‐Uk 2016;6:31391.
- Atashrazm F, Hammond D, Perera G, et al. LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disord 2019;34:406–415.
- Dzamko N, Chua G, Ranola M, Rowe DB, Halliday GM. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J Park Dis 2013;3:145–152.
Source: PubMed